NCT05136885View on ClinicalTrials.gov

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

SLS-005

Administration: Infusion Dose: 0.75 g/kg weekly

DRUG

Matching Placebo

Administration: Infusion Dose: equivalent weight-based volume as described for trehalose

Trial Locations (1)

02114

Healey Center for ALS at Mass General, Boston

All Listed Sponsors
collaborator

Seelos Therapeutics, Inc.

INDUSTRY

lead

Merit E. Cudkowicz, MD

OTHER